Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Ra Medical Systems Inc. (RMED) Message Board

$VTAK CATHETER PRECISION, INC. (VTAK) Reports Unau

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 91
(Total Views: 148)
Posted On: 01/11/2024 8:01:27 AM
Avatar
Posted By: louied91
$VTAK CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results

https://www.accesswire.com/823629/catheter-pr...23-results

FORT MILL, SC / ACCESSWIRE / January 10, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights and unaudited preliminary annual and fourth quarter results of 2023.

Unaudited preliminary results of the fourth quarter and year ended December 31, 2023, include the following:

Total revenues for the quarter and year ended December 31, 2023, were approximately $129,000 and $442,000, respectively.
Total cash on hand as of December 31, 2023, was approximately $3.6 million.
Total assets as of December 31, 2023, subject to adjustment, was $30.7 million.
Shareholders equity as of December 31, 2023, subject to adjustment was $19.4 million.
Preliminary net loss, subject to adjustment for the quarter and year ended December 31, 2023, was approximately ($2.5) million and ($72.4) million, respectively. A one-time $61 million write off for impairment of goodwill is reflected in the net loss for the year ended December 31, 2023.
Highlights of the year ended December 31, 2023, include the following:

Onboarded and trained sales and clinical personnel in the US.
Launched LockeT closure product in the US.
Completed enrollment of Phase I LockeT study including more than 100 patients with a completed and submitted manuscript.
Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT.
Finalized new build processes for VIVO disposable component to reduce manufacturing costs.
Received approval for first VIVO purchase in France. VIVO is now active in six European countries.
Continued expansion of our intellectual property (IP), now having 50 patents worldwide.
David Jenkins, CEO, commented: "We have a lot of momentum as we move into 2024. Our sales and clinical team have successfully introduced VIVO and LockeT to new hospital centers and the products have been well received. Over the next several months we expect hospital approval to begin additional product evaluations and subsequent purchase orders. Catheter Precision's VIVO System continues to support the electrophysiologist and hospital in growing their ventricular ablation programs, which we believe will rival the atrial fibrillation market in the future. LockeT offers a more affordable and easier to use option for wound closure and the first manuscript demonstrating these benefits has been submitted for publication and should be available soon."

These preliminary results are based on management's initial analysis of operations for the quarter and year ended December 31, 2023, and are subject to completion of the Company's year-end financial reporting processes, further internal review, potential adjustments and audit by the Company's external auditors. Items to further consider in the completion of the results include the analysis of impairment to intangible assets and liabilities pertaining to potential royalties payable in the future, which could materially impact our final results.


(0)
(0)




Ra Medical Systems Inc. (RMED) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us